Compare Marqeta Inc (MQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs TransMedics Group Inc — how do they compare? Marqeta Inc trades at $18.11 (market cap $1.82B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Marqeta Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and TransMedics Group Inc for 24 Days on average.
| MQ | TMDX | |
|---|---|---|
Market Cap | $1.82B | $2.74B |
Volume | 1,126,466 | 949,331 |
Sector | Technology | Health |
52-Week High | $20.32 | $150.42 |
52-Week Low | $15.04 | $61.99 |
Typical Hold Time | 44 Days | 24 Days |
Enterprise Value | $1.13B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MQ trades at $17.44, up 2.23% today, with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q3 2026 results due November 3. Revenue grew to $625M in 2025, but net income was negative. Analyst consensus is mixed, with 32% buy ratings but a price target of $11.38, below the current price. Recent news includes partnerships with BVNK for stablecoin cards and Google for wallet expansions.
MQ shows operational improvement with positive cash flow in 2025, but high valuation ratios and thin margins pose risks. The stock faces headwinds from contract renewals in Q3 2026, which may slow growth. Upside depends on sustained earnings beats and successful product expansions. Investors should weigh the bullish technicals against fundamental challenges and analyst caution.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
